A five-year follow-up study of 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices regarding care.
- A Touchy Subject
- Clovis Oncology Rubraca rucaparib granted FDA priority review for advanced prostate cancer
- Fostering Sexual Health and Intimacy
- A predictive model for prostate cancer incorporating PSA molecular forms and age
- Artificial intelligence (AI) can be used to detect and grade prostate cancer